A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial

European Journal of Cancer

Volumn 49, Issue 13, 2013, Pages 2869-2876

  Morschhauser, Franck ^a   Fitoussi, Olivier ^b   Haioun, Corinne ^c,d   Thieblemont, Catherine ^e   Quach, Hang ^f   Delarue, Richard ^g   Glaisner, Sylvie ^h   Gabarre, Jean ⁱ   Bosly, André ^j   Lister, John ^k   Li, Ju ^l   Coiffier, Bertrand ^m  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Polyclinique Bordeaux Nord   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f ST VINCENT S HOSPITAL   (Australia)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h CENTRE RENÉ HUGUENIN   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^k WESTERN PENNSYLVANIA HOSPITAL   (United States)

^l CELGENE CORPORATION   (United States)

^m HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

EXPECT; Lenalidomide; lymphoma; Phase 2; T cell non Hodgkin

Indexed keywords

LENALIDOMIDE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALLERGIC REACTION; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CONSTIPATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; HYPERSENSITIVITY; INFECTION; LUNG ADENOCARCINOMA; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEOPLASM; NEUTROPENIA; NONHODGKIN LYMPHOMA; OPEN STUDY; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SECOND CANCER; SEPSIS; SINGLE BLIND PROCEDURE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR FLARE; VEIN EMBOLISM; VEIN THROMBOSIS;

EXPECT; LENALIDOMIDE; PHASE 2; T-CELL NON-HODGKIN LYMPHOMA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EARLY TERMINATION OF CLINICAL TRIALS; EUROPE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84881109532     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.04.029     Document Type: Article

References (30)

1. B.D. Cheson, S.J. Horning, and B. Coiffier Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1999 1244 1253
2. B. Coiffier, N. Brousse, and M. Peuchmaur Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives) Ann Oncol 1 1990 45 50
3. B. Coiffier, B. Pro, and H.M. Prince Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy J Clin Oncol 30 2012 631 636
4. F. d'Amore, J. Radford, and T. Relander Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma Br J Haematol 150 2010 565 573
5. N.H. Dang, F.B. Hagemeister, and M. Duvic Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes Oncol Rep 10 2003 1513 1518
6. M.H. Delfau-Larue, L. de Leval, and B. Joly Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA Haematologica 97 2012 1594 1602
7. M.A. Dimopoulos, P.G. Richardson, and N. Brandenburg A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide Blood 119 2012 2764 2767
8. K. Dredge, R. Horsfall, and S.P. Robinson Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Microvasc Res 69 2005 56 63
9. G. Dueck, N. Chua, and A. Prasad Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma Cancer 116 2010 4541 4548
10. H.E. Eve, and S.A. Rule Lenalidomide-induced tumour flare reaction in mantle cell lymphoma Br J Haematol 151 2010 410 412
11. P. Fenaux, A. Giagounidis, and D. Selleslag A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q Blood 118 2011 3765 3776
12. F.M. Foss, P.L. Zinzani, J.M. Vose, R.D. Gascoyne, S.T. Rosen, and K. Tobinai Peripheral T-cell lymphoma Blood 117 2011 6756 6767
13. T. Ishida, T. Joh, and N. Uike Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study J Clin Oncol 30 2012 837 842
14. O.A. O'Connor, B. Pro, and L. Pinter-Brown Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study J Clin Oncol 29 2011 1182 1189
15. B. Pohlman, R. Advani, and M. Duvic Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma Blood 114 2009 [abstract 920]
16. H.M. Prince, M. Duvic, and A. Martin Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma J Clin Oncol 28 2010 1870 1877
17. B. Pro, R. Advani, and P. Brice Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study J Clin Oncol 30 2012 2190 2196
18. W. Qi, C. Spier, and X. Liu Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment Leuk Res 2012 10.1016/j.leukres.2012.10.017
19. C. Querfeld, T.M. Kuzel, J. Guitart, and S.T. Rosen Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma Hematol Meet Rep 3 2009 < http://www.pagepress.org/journals/index.php/hmr/article/view/546 > [accessed 03 Dec. 2012]
20. C. Querfeld, T.M. Kuzel, and Y.H. Kim Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma Leuk Lymphoma 52 2011 1474 1480
21. A.G. Ramsay, A.J. Clear, and G. Kelly Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy Blood 114 2009 4713 4720
22. N. Reddy, F.J. Hernandez-Ilizaliturri, and G. Deeb Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo Br J Haematol 140 2008 36 45
23. P. Richardson, S. Jagannath, and M. Hussein Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma Blood 114 2009 772 778
24. S.H. Swerdlow, E. Campo, and N.L. Harris WHO classification of tumours of haematopoietic and lymphoid tissues 4th ed. 2008 WHO Press Geneva
25. S.J. Whittaker, M.F. Demierre, and E.J. Kim Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma J Clin Oncol 28 2010 4485 4491
26. T.E. Witzig, J.M. Vose, and P.L. Zinzani An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma Ann Oncol 22 2011 1622 1627
27. D. Zhu, L.G. Corral, Y.W. Fleming, and B. Stein Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation Cancer Immunol Immunother 57 2008 1849 1859
28. P.L. Zinzani, G. Musuraca, and M. Tani Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma J Clin Oncol 25 2007 4293 4297
29. P.L. Zinzani, C. Pellegrini, and A. Broccoli Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified Leuk Lymphoma 52 2011 1585 1588
30. P.L. Zinzani, F. Venturini, and V. Stefoni Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome Ann Oncol 21 2010 860 863